The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Merck (NYSE:MRK) has received FDA approval for Enflonsia, a prophylactic antibody therapy designed to protect infants from ...

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's ...

Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...